A comprehensive review of small-molecule drugs for the treatment of type 2 diabetes mellitus: Synthetic approaches and clinical applications,European Journal of Medicinal Chemistry

当前位置： X-MOL 学术 › Eur. J. Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A comprehensive review of small-molecule drugs for the treatment of type 2 diabetes mellitus: Synthetic approaches and clinical applications
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2024-01-28 , DOI: 10.1016/j.ejmech.2024.116185
Yuan-Yuan Guo ₁ , Jing-Yi Zhang ₂ , Jin-Feng Sun ₃ , Hua Gao ₄

Affiliation

Type 2 diabetes mellitus (T2DM) is a long-term metabolic disorder characterized by the body's resistance to insulin and inadequate production of insulin. Small molecule drugs to treat T2DM mainly control blood sugar levels by improving insulin sensitivity, increasing insulin secretion, or reducing liver glycogen production. With the deepening of research on the pathogenesis of diabetes, many drugs with new targets and mechanisms of action have been discovered. The targets of the drugs for T2DM are mainly dipeptidyl peptidase IV inhibitors (DPP4), sodium/glucose cotransporter 2 inhibitors (SGLT2), sulfonylurea receptor modulators (SUR), peroxisome proliferator-activated receptor γ agonists (PPARγ), etc. We are of the opinion that acquiring a comprehensive comprehension of the synthetic procedures employed in drug molecule production will serve as a source of inventive and pragmatic inspiration for the advancement of novel, more potent, and feasible synthetic methodologies. This review aims to outline the clinical applications and synthetic routes of some representative drugs to treat T2DM, which will drive the discovery of new, more effective T2DM drugs.

中文翻译：

小分子药物治疗 2 型糖尿病的小分子药物综合综述：合成方法和临床应用

2 型糖尿病（T2DM）是一种长期代谢紊乱，其特征是身体对胰岛素的抵抗和胰岛素产生不足。治疗 T2DM 的小分子药物主要通过提高胰岛素敏感性、增加胰岛素分泌或减少肝糖原的产生来控制血糖水平。随着对糖尿病发病机制研究的深入，已经发现了许多具有新靶点和作用机制的药物。T2DM药物的靶点主要是二肽基肽酶IV抑制剂（DPP4）、钠/葡萄糖协同转运蛋白2抑制剂（SGLT2）、磺酰脲类受体调节剂（SUR）、过氧化物酶体增殖物激活受体γ激动剂（PPARγ）等。我们认为，全面了解药物分子生产中采用的合成程序将成为创新和实用灵感的来源，以推进新颖、更有效和可行的合成方法。本文旨在概述一些治疗 T2DM 的代表性药物的临床应用和合成路线，这将推动新的、更有效的 T2DM 药物的发现。

更新日期：2024-01-28

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南